medigraphic.com
ISSN 0016-3813 (Print)

2014, Number 2

<< Back Next >>

Gac Med Mex 2014; 150 (2)

Prevalence of dyslipidemias in Mexico city and Its relation to other cardiovascular risk factors. Results from the CARMELA study

Escobedo-de la Peña J, de Jesús-Pérez R, Schargrodsky H, Champagne B

Language: Spanish
References: 27
Page: 128-136
PDF size: 91.58 Kb.


ABSTRACT

Objective: To estimate the prevalence of dyslipidemias in Mexico city and its relation to other cardiovascular risk factors. Methods: A cross sectional study was conducted to measure cardiovascular risk factors in Mexico City. All subjects were interviewed and anthropometric measures performed, as well as cholesterol, high-density lipoproteins (HDL-C) and triglycerides. Low-density lipoprotein (LDL-C) values were calculated. Means- as well as dyslipidemia-weighted prevalence were measured, with 95% confidence intervals. Results: 833 males and 889 females were studied. The prevalence of cholesterol ≥ 240 mg/dl was 16.4% (95% CI: 14.2-18.7), and 34.1% (95% CI: 31.6-36.5) had values between 200 and 240 mg/dl. Very high values of triglycerides were seen in 2.6% of studied subjects and 29.9% (95% CI: 26.9-32.8) had high values. The prevalence of hypertriglyceridemia was higher in males (43.3%) than females (23%). Mean values of assessed parameters were in general higher in those with other cardiovascular risk factors. Conclusions: Lipid values in the population of Mexico City are high and so is the prevalence of dyslipidemias. There is an urgent need to implement health policies directed to diminish cardiovascular risk factors, mainly dyslipidemias.


REFERENCES

  1. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791-8.

  2. Grundy SM, Cleeman JI, Merz CNB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39.

  3. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753): 1670-81.

  4. Camacho Hernández R, Corona Muñiz I, Vázquez Martínez JL, Martínez Rodríguez F, Escobedo de la Peña J. Factores de riesgo para cardiopatía isquémica en México: un estudio de casos clínicos y testigos. Arch Inst Cardiol Méx. 1995;65(4):315-22.

  5. Unzueta-Montoya A, Escobedo-de la Peña J, Torres-y Gutiérrez Rubio A, et al. Risk factors related to the occurrence of silent myocardial ischemia in Mexicans. Clin Cardio. 2000;23(4):248-52.

  6. Escobedo de la Peña J, Escamilla Cejudo JA, Santos-Burgoa C. Colesterol sérico y diabetes mellitus: principales factores de riesgo independientes en la mortalidad por cardiopatía isquémica en México. Arch Inst Cardiol Mex. 1994;64(2):189-95.

  7. Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A. Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of population-based studies carried out from 1979 to 2002. Eur J Cardiov Prev Rehabil. 2003;10(6):411-9.

  8. Aguilar-Salinas CA, Valles V, Ríos Torres JM, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J. Lipid Res. 2001;42(8):1298-307.

  9. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. Características de los casos con dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedades Crónicas. Salud Publica Mex. 2002;44(6):546-53.

  10. Lara A, Rosas M, Pastelón G, Aguilar C, Attie F, Velázquez Monroy O. Hipercolesterolemia e hipertensión arterial en México. Consolidación urbana actual con obesidad, diabetes y tabaquismo. Arch Cardiol Mex. 2004;74(3):231-45.

  11. Acosta-Cázares B, Escobedo-de la Peña J. High burden of cardiovascular disease risk factors in Mexico: An epidemic of ischemic heart disease that may be on its way? Am Heart J. 2010;160(2):230-6.

  12. Secretaría de Salud. Sistema Nacional de Información en Salud. Información 2000-2008: Principales causas de mortalidad en mujeres y en hombres. Dirección General de Información en Salud. Actualizado el 27 de octubre de 2010. Consultado el 27 de febrero de 2011. Disponible en: http://sinais.salud.gob.mx/mortalidad/index.html

  13. Schargrodsky H, Hernández-Hernández R, Champagne BM, et al. CARMELA: Assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008;121(1):58-65.

  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.

  15. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.

  16. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294(14):1773-81.

  17. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex. 2010;52 Suppl 1:S72-9.

  18. Vinueza R, Boissonnet CP, Acevedo M, et al.; on behalf of the CARMELA Study Investigators. Dyslipidemia in seven Latin American cities: CARMELA study. Prev Med. 2010;50(3):106-11.

  19. Briel M, Ignacio Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92 doi:10.1136/bmj.b92.

  20. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA. 2009;302(19):2104-10.

  21. Costa J, Borges M, David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332(7550):1115-24.

  22. Gómez-Pérez FJ, Rojas R, Villalpando S, Barquera S, Rull J, Aguilar- Salinas CA. Prevention of cardiovascular disease based on lipid lowering treatment: a challenge for the Mexican health system. Salud Publica Mex. 2010;52 Suppl 1:S54-62.

  23. Rodríguez Abrego G, Escobedo de la Peña J, Zurita B, Ramírez TJ. Muerte prematura y discapacidad en los derechohabientes del Instituto Mexicano del Seguro Social. Salud Publica Mex. 2007;49: 134-45.

  24. Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens. 2007;25(8):1578-82.

  25. Law M R, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324(7353):1570-6.

  26. Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet. 2008;371(9623):1547-9.

  27. Najjar SS, Scuteri A, Lakatia EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension. 2005;46(3):454-62.




2020     |     www.medigraphic.com